As PCI Biotech’s limited operations were contingent upon sustained external interest, all R&D operations will now be discontinued, the company states.

In recent months, various strategic alternatives have been explored, and this process continues. The evaluation is made with careful consideration of the company’s circumstances, and includes a range of options, including, but not limited to, a merger or a structured wind-up of the company, describes the company.

The liquidity position of the PCI Biotech group remains critical, and there is no assurance that additional financing can be secured. These material uncertainties cast significant doubt on the PCI Biotech group’s ability to continue as a going concern.

Further information will be communicated as and when appropriate, concludes the company in its press release.